References
1 Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol . 2010;85(3):174-180.
2 Bergmann AK, Grace RF, Neufeld EJ. Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol . 2010;89 Suppl 1(Suppl 1):S95-103.
3 Cheng CN, Yang YN, Yeh YH, Chen LW, Chen JS, Lin YC. Predictors of Remission in Severe Childhood Immune Thrombocytopenia. Diagnostics (Basel) . 2023;13(3).
4 Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf . 2017;16(3):411-419.
5 Arachchillage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. Int J Mol Sci . 2023;24(2).
6 Eryavuz Onmaz D, Tezcan D, Abusoglu S, Yilmaz S, Yerlikaya FH, Onmaz M, et al. Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. Inflammopharmacology . 2021;29(6):1795-1805.
7 Ducassou S, Gourdonneau A, Fernandes H, Leverger G, Pasquet M, Fouyssac F, et al. Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol . 2020;189(5):931-942.
8 Bockow B, Kaplan TB. Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports. J Med Case Rep . 2013;791.
9 Brik-Simon D, Efros O, Levinsky Y, Amarilyo G, Tirosh I, Levy-Mendelovich S, et al. Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE-related immune thrombocytopenia. Pediatr Blood Cancer . 2024;71(5):e30911.
10 Wang YM, Yu YF, Liu Y, Liu S, Hou M, Liu XG. The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. Hematology . 2020;25(1):139-144.
11 Abbasi SY, Milhem M, Zaru L. A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura. Ann Hematol . 2008;87(6):459-462.
12 Baysal M, Bas V, Umit E, Kirkizlar HO, Demir AM. Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? Turk J Haematol . 2022;39(1):38-42.
13 Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest Package: Tests in Linear Mixed Effects Models. Journal of Statistical Software . 2017;82(13):1 - 26.
14 Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software . 2015;67(1):1 - 48.
15 Roche O, Aladjidi N, Rakotonjanahary J, Leverger G, Leblanc T, Thomas C, et al. Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP). Am J Hematol . 2017;92(5):E79-E81.
16 Khellaf M, Chabrol A, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol . 2014;89(2):194-198.
17 Ferreira PMP, Sousa RWR, Ferreira JRO, Militao GCG, Bezerra DP. Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms. Pharmacol Res . 2021;168105582.
18 Liu Z, Mei T. Immune thrombocytopenia induces autophagy and suppresses apoptosis in megakaryocytes. Mol Med Rep . 2018;18(4):4016-4022.
19 Mohammadpour F, Kargar M, Hadjibabaie M. The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature. J Res Pharm Pract . 2018;7(1):4-12.
20 Gheet FS, Dawoud HE, El-Shahaby WA, Elrifaey SM, Abdelnabi HH. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. Eur J Pediatr . 2023.
21 Gisondi P, Piaserico S, Bordin C, Bellinato F, Tozzi F, Alaibac M, et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol . 2021;39(5):1099-1107.
22 Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology (Oxford) . 2016;55(6):957-967.
23 Kazi MS, Saurabh K, Rishi P, Rishi E. Delayed onset chloroquine retinopathy presenting 10 years after long-term usage of chloroquine.Middle East Afr J Ophthalmol . 2013;20(1):89-91.